相关实验视频
Updated: Jun 21, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.4K
代氧化物不响应的先天性高胰岛素症的临床管理:单中心经验
Kei Takasawa1, Ryosei Iemura1, Ryuta Orimoto1
1Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
概括
先天性高胰岛素症 (CHI) 的管理是复杂的. 本案例系列强调了更新的策略,包括基因诊断和持续血糖监测 (CGM),以改善对二氧化无反应性CHI的治疗结果.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 代谢障碍 代谢障碍 代谢障碍
- 遗传学 遗传学是一种遗传学.
背景情况:
- 先天性高胰岛素症 (CHI) 是婴儿和儿童持续低血糖的主要原因.
- 虽然有进展,但在管理对二氧化无反应性CHI方面仍然存在挑战.
- 新的国际指导方针为CHI治疗提供了最新的方法.
关键词:
ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC is also known by the name ofKCNJ1111 在线观看遗传性高胰岛素症是一种先天性高胰岛素症.不断监测葡萄糖的情况.兰雷化物是什么相关概念视频
Insulin: Dosing Regimen and Adverse Effects
165
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Hypoglycemia and Glucagon
254
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
254
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187

